+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-03-22Number of Pages: 143

Chronic Kidney Disease (CKD) Drugs Market (Drug Class - ACE Inhibitors, Angiotensin-II Receptor Blockers, Calcium Channel Blockers, Beta Blockers, Erythropoiesis - stimulating Agents (ESAs), and Diuretics; End User - Hospitals and Specialty Clinics) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Global Chronic Kidney Disease Drugs Market: Snapshot

The global market for chronic kidney disease drugs continues to proliferate at a significant pace, driven by the increasing number of chronic kidney disease patients and the growing need of novel treatments to improve patients’ quality of life. The increasing number of elderly people, who are more vulnerable to various diseases due to poor immunity, such as cardiovascular disorders, diabetes, and neurological conditions, is another important factor behind the growth of this market, as, owing to this, the prevalence of these diseases is rising considerably across the world.

Going forward, the market is projected to be propelled substantially in the near future by the technological advancements, leading to the development of a wide array of drugs, which will enable clinicians to provide proper assistance to chronic kidney disease patients. The global chronic kidney disease drugs market stood at US$11.5 bn in 2015. Burgeoning at a CAGR of 3.60% between 2016 and 2024, the market’s opportunity is expected to reach US$15.8 bn by the end of 2024.

chronic kidney disease drugs market

Calcium Channel Blockers to Remain Market Leader Supported by Strong Demand

The global market for chronic kidney disease drugs is studied on the basis of a number of parameters, among which the drug class is a prominent one. Based on the drug class, the market is classified primarily into ACE Inhibitors, Angiotensin-II receptor blockers, calcium channel blockers, beta blockers, erythropoiesis-stimulating agents (ESAs), and diuretics.

Calcium channel blockers surfaced as the key drug class in 2015, leading the market with a share of 18.9%. Currently, the main calcium channel blockers utilized across the world are benzothiazepines (diltiazem), phenyl alkyl amines (verapamil), and dihydropiridines (nifedipine and amlodipine).

Hospitals and specialty clinics are the prime end users of chronic kidney disease drugs. The hospitals segment, which is the current market leader, is expected to continue its dominance in this market over the next few years.

Strong Economic Conditions to Prove Favorable for North America Chronic Kidney Disease Drugs Market

The worldwide chronic kidney disease drugs market is stretched across North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America led this market in 2015 with a share of 31.8%. Driven by the strong economic condition of the region and the high acceptance for advanced technology products, the North America chronic kidney disease drugs market is likely to maintain its lead over the forthcoming years. The increasing cases of diabetes and obesity related disorders are also projected to boost this regional market in the near future.

Europe, which was the second leading market for chronic kidney disease drugs across the world in 2015, is likely to present the most attractive growth opportunities to market players in the years to come due to the increasing pool of kidney cancer patients in this region. The high rate of adoption and usage of superior quality treatments for these diseases is also predicted to aid the Europe chronic kidney disease drugs market over the next few years. The significant expansion of the medical and healthcare industry in China, Japan, and Australia is likely to drive the Asia Pacific market for chronic kidney disease drugs in the near future.

Teva Pharmaceutical Industries Ltd., Amgen Inc., AstraZeneca Plc, Pfizer Inc., F. Hoffmann-La Roche Ltd., Sanofi S.A., GlaxoSmithKline Plc, AbbVie Inc., Kissei Pharmaceutical Co. Ltd., and Keryx Biopharmaceuticals Inc. are some of the leading makers of drugs for the treatment of chronic kidney diseases across the world.

Section 1 Preface 
1.1 Report Scope and Market Segmentation 
1.2 Research Highlights

Section 2 Assumptions and Research Methodology 
2.1 Assumptions
2.2 Research Methodology

Section 3 Executive Summary
3.1 Global Chronic Kidney Disease (CKD) Drugs: Market Snapshot
3.2 Market Share Analysis by Region, 2015
3.3 Global Chronic Kidney Disease (CKD) Drugs Market: Opportunity Map

Section 4 Market Overview
4.1 Market Overview
4.2 Global Chronic Kidney Disease (CKD) Drugs Market: Market Indicators
4.3 Global Chronic Kidney Disease (CKD) Drugs Market: Market Outlook

Section 5 Pipeline Analysis
5.1 Chronic Kidney Disease (CKD) Drugs Market: Recent Approvals
5.2 Chronic Kidney Disease (CKD) Drugs Market: Pipeline Analysis
5.3 Global Chronic Kidney Disease (CKD) Pipeline Drugs Market Size (US$ Mn) Forecast, 2018–2024

Section 6 Market Dynamics
6.1 Drivers and Restraints Snapshot Analysis
6.2 Drivers
      6.2.1 High prevalence of chronic kidney disease (CKD) worldwide
      6.2.2 Promising pipeline and approval of novel molecules
      6.2.3 Shift toward value-based health care model
      6.2.4 Rise in incidence of cardiovascular disorders and diabetes
      6.2.6 Increase in health care spending & improvement in health care infrastructure
      6.2.6 Increase in global geriatric population
6.3 Restraints
      6.3.1 Competition from biosimilars due to patent loss
      6.3.2 Increase in preference for generic drug variants
      6.3.3 Change in reimbursement scenario 
6.4 Opportunities
      6.4.1 Focusing on emerging markets
      6.4.2 Novel therapeutic approaches such as stem cell therapy
6.5 Key Trends
6.6 Global Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, 2014–2024
6.7 Global Chronic Kidney Disease Drugs Market: Porter’s Analysis 

Section 7 Chronic Kidney Disease (CKD) Drugs Market Analysis, by Drug Class
7.1 Introduction
7.2 Global Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Drug Class
7.3 Chronic Kidney Disease (CKD) Drugs Market Forecast, by Drug Class 
      7.3.1 ACE Inhibitors
      7.3.2 Angiotensin-II Receptor Blockers
      7.3.3 Calcium Channel Blockers
      7.3.4 Beta Blockers
      7.3.5 Erythropoiesis-stimulating Agents (ESAs)
      7.3.6 Diuretics
      7.3.7 Others
7.5 Market Attractiveness Analysis, by Drug Class

Section 8 Chronic Kidney Disease (CKD) Drugs Market Analysis, by End-user
8.1 Introduction
8.2 Global Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by End-user
8.3 Chronic Kidney Disease (CKD) Drugs Market Forecast, by End-user
      8.3.1 Hospitals
      8.3.2 Specialty Clinics
8.4 Market Attractiveness Analysis, by End-user

Section 9 Chronic Kidney Disease (CKD) Drugs Market Analysis, by Region
9.1 Global Chronic Kidney Disease (CKD) Drugs Market Snapshot, by Country
9.2 Global Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Region
9.3 Chronic Kidney Disease (CKD) Drugs Market Forecast, by Region
9.4 Market Attractiveness Analysis, by Region

Section 10 North America Chronic Kidney Disease (CKD) Drugs Market Analysis
10.1 Market Overview
10.2 Market Analysis, by Drug Class
      10.2.1 Market Value Share Analysis, by Drug Class
      10.2.2 Market Size (US$ Mn) Forecast, by Drug Class
              10.2.2.1 ACE Inhibitors
              10.2.2.2 Angiotensin-II Receptor Blockers
              10.2.2.3 Calcium Channel Blockers
              10.2.2.4 Beta Blockers
              10.2.2.5 Erythropoiesis-stimulating Agents (ESAs)
              10.2.2.6 Diuretics
              10.2.2.7 Others
10.3 Market Analysis, by End-user
      10.3.1 Market Value Share Analysis, by End-user
      10.3.2 Market Size (US$ Mn) Forecast, by End-user
              10.3.2.1 Hospitals
              10.3.2.2 Specialty Clinics
10.4 Market Analysis, by Country
      10.4.1 Market Value Share Analysis, by Country
      10.4.2 Market Size (US$ Mn) Forecast, by Country, 2016–2024
              10.4.2.1 U.S.
              10.4.2.2 Canada
10.5 Market Attractiveness Analysis
      10.5.1 by Drug Class 
10.5.2 by End-user
10.5.3 by Country

Section 11 Europe Chronic Kidney Disease (CKD) Drugs Market Analysis
11.1 Market Overview
11.2 Market Analysis, by Drug Class
      11.2.1 Market Value Share Analysis, by Drug Class
      11.2.2 Market Size (US$ Mn) Forecast, by Drug Class
              11.2.2.1 ACE Inhibitors
              11.2.2.2 Angiotensin-II Receptor Blockers
              11.2.2.3 Calcium Channel Blockers
              11.2.2.4 Beta Blockers
              11.2.2.5 Erythropoiesis-stimulating Agents (ESAs)
              11.2.2.6 Diuretics
              11.2.2.7 Others
11.3 Market Analysis, by End-user
      11.3.1 Market Value Share Analysis, by End-user
      11.3.2 Market Size (US$ Mn) Forecast, by End-user
              11.3.2.1 Hospitals
              11.3.2.2 Specialty Clinics
11.4 Market Analysis, by Country
      11.4.1 Market Value Share Analysis, by Country
      11.4.2 Market Size (US$ Mn) Forecast, by Country, 2016–2024
              11.4.2.1 U.K.
              11.4.2.2 Germany
              11.4.2.3 France
              11.4.2.4 Spain
              11.4.2.5 Italy
              11.4.2.6 Rest of Europe
11.5 Market Attractiveness Analysis
      11.5.1 by Drug Class 
      11.5.2 by End-user
      11.5.3 by Country

Section 12 Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Analysis
12.1 Market Overview
12.2 Market Analysis, by Drug Class
      12.2.1 Market Value Share Analysis, by Drug Class
      12.2.2 Market Size (US$ Mn) Forecast, by Drug Class
              12.2.2.1 ACE Inhibitors
              12.2.2.2 Angiotensin-II Receptor Blockers
              12.2.2.3 Calcium Channel Blockers
              12.2.2.4 Beta Blockers
              12.2.2.5 Erythropoiesis-stimulating Agents (ESAs)
              12.2.2.6 Diuretics
              12.2.2.7 Others
12.3 Market Analysis, by End-user
      12.3.1 Market Value Share Analysis, by End-user
      12.3.2 Market Size (US$ Mn) Forecast, by End-user
              12.3.2.1 Hospitals
              12.3.2.2 Specialty Clinics
12.4 Market Analysis, by Country
      12.4.1 Market Value Share Analysis, by Country
      12.4.2 Market Size (US$ Mn) Forecast, by Country, 2016–2024
              12.4.2.1 China
              12.4.2.2 Japan
              12.4.2.3 Australia
              12.4.2.4 India
              12.4.2.5 Rest of Asia Pacific
12.5 Market Attractiveness Analysis
      12.5.1 by Drug Class 
      12.5.2 by End-user
      12.5.3 by Country

Section 13 Latin America Chronic Kidney Disease (CKD) Drugs Market Analysis
13.1 Market Overview
13.2 Market Analysis, by Drug Class
      13.2.1 Market Value Share Analysis, by Drug Class
      13.2.2 Market Size (US$ Mn) Forecast, by Drug Class
              13.2.2.1 ACE Inhibitors
              13.2.2.2 Angiotensin-II Receptor Blockers
              13.2.2.3 Calcium Channel Blockers
              13.2.2.4 Beta Blockers
              13.2.2.5 Erythropoiesis-stimulating Agents (ESAs)
              13.2.2.6 Diuretics
              13.2.2.7 Others
13.3 Market Analysis, by End-user
      13.3.1 Market Value Share Analysis, by End-user
      13.3.2 Market Size (US$ Mn) Forecast, by End-user
              13.3.2.1 Hospitals
              13.3.2.2 Specialty Clinics
13.4 Market Analysis, by Country
      13.4.1 Market Value Share Analysis, by Country
      13.4.2 Market Size (US$ Mn) Forecast, by Country, 2016–2024
              13.4.2.1 Brazil
              13.4.2.2 Mexico
              13.4.2.3 Rest of LATAM
13.5 Market Attractiveness Analysis
      13.5.1 by Drug Class 
      13.5.2 by End-user
      13.5.3 by Country

Section 14 Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Analysis
14.1 Market Overview
14.2 Market Analysis, by Drug Class
      14.2.1 Market Value Share Analysis, by Drug Class
      14.2.2 Market Size (US$ Mn) Forecast, by Drug Class
              14.2.2.1 ACE Inhibitors
              14.2.2.2 Angiotensin-II Receptor Blockers
              14.2.2.3 Calcium Channel Blockers
              14.2.2.4 Beta Blockers
              14.2.2.5 Erythropoiesis-stimulating Agents (ESAs)
              14.2.2.6 Diuretics
              14.2.2.7 Others
14.3 Market Analysis, by End-user
      14.3.1 Market Value Share Analysis, by End-user
      14.3.2 Market Size (US$ Mn) Forecast, by End-user
              14.3.2.1 Hospitals
              14.3.2.2 Specialty Clinics
14.4 Market Analysis, by Country
      14.4.1 Market Value Share Analysis, by Country
      14.4.2 Market Size (US$ Mn) Forecast, by Country, 2016–2024
              14.4.2.1 South Africa
              14.4.2.2 Saudi Arabia
              14.4.2.3 Rest of MEA
14.5 Market Attractiveness Analysis
      14.5.1 by Drug Class 
      14.5.2 by End-user
      14.5.3 by Country

Section 15 Company Profiles
15.1 Chronic Kidney Disease (CKD) Drugs Market Share Analysis, by Company (2015)
15.2 Company Profiles
      15.2.1 Keryx Biopharmaceuticals, Inc. 
              15.2.1.1 Company Overview (HQ, Business Segments, Employee Strength)
              15.2.1.2 Financial Overview
              15.2.1.3 Product Portfolio
              15.2.1.4 SWOT Analysis
              15.2.1.5 Strategic Overview
      15.2.2 Kissei Pharmaceutical Co., Ltd
              15.2.2.1 Company Overview (HQ, Business Segments, Employee Strength)
              15.2.2.2 Financial Overview
              15.2.2.3 Product Portfolio
              15.2.2.4 SWOT Analysis
              15.2.2.5 Strategic Overview
      15.2.3 AbbVie, Inc.
              15.2.3.1 Company Overview (HQ, Business Segments, Employee Strength)
              15.2.3.2 Financial Overview
              15.2.3.3 Product Portfolio
              15.2.3.4 SWOT Analysis
              15.2.3.5 Strategic Overview
      15.2.4 GlaxoSmithKline plc.
              15.2.4.1 Company Overview (HQ, Business Segments, Employee Strength)
              15.2.4.2 Financial Overview
              15.2.4.3 Product Portfolio
              15.2.4.4 SWOT Analysis
              15.2.4.5 Strategic Overview
      15.2.5 Sanofi S.A. 
              15.2.5.1 Company Overview (HQ, Business Segments, Employee Strength)
              15.2.5.2 Financial Overview
              15.2.5.3 Product Portfolio
              15.2.5.4 SWOT Analysis
              15.2.5.5 Strategic Overview
      15.2.6 F. Hoffmann-La Roche Ltd. 
              15.2.6.1 Company Overview (HQ, Business Segments, Employee Strength)
              15.2.6.2 Financial Overview
              15.2.6.3 Product Portfolio
              15.2.6.4 SWOT Analysis
              15.2.6.5 Strategic Overview
      15.2.7 Pfizer, Inc. 
              15.2.7.1 Company Overview (HQ, Business Segments, Employee Strength)
              15.2.7.2 Financial Overview
              15.2.7.3 Product Portfolio
              15.2.7.4 SWOT Analysis
              15.2.7.5 Strategic Overview
      15.2.8 AstraZeneca plc
              15.2.8.1 Company Overview (HQ, Business Segments, Employee Strength)
              15.2.8.2 Financial Overview
              15.2.8.3 Product Portfolio
              15.2.8.4 SWOT Analysis
              15.2.8.5 Strategic Overview
      15.2.9 Amgen Inc. 
              15.2.9.1 Company Overview (HQ, Business Segments, Employee Strength)
              15.2.9.2 Financial Overview
              15.2.9.3 Product Portfolio
              15.2.9.4 SWOT Analysis
              15.2.9.5 Strategic Overview
      15.2.10 Teva Pharmaceutical Industries Ltd. 
              15.2.10.1 Company Overview (HQ, Business Segments, Employee Strength)
              15.2.10.2 Financial Overview
              15.2.10.3 Product Portfolio
              15.2.10.4 SWOT Analysis
              15.2.10.5 Strategic Overview

List of Figures

Figure 01: Global Parsabiv (Etelcalcitide) Market Revenue, 2018 – 2024 (US$ Mn)
Figure 02: Global Forxiga (Dapagliflozin Market Revenue, 2021 – 2024 (US$ Mn)
Figure 03: Global Roxadustat (FG-4592) Market Revenue, 2018 – 2024 (US$ Mn)
Figure 04: Global Daprodustat Market Revenue, 2020 – 2024 (US$ Mn)
Figure 05: Global Vadadustat Market Revenue, 2020 – 2024 (US$ Mn)
Figure 06: Global Alpharen Market Revenue, 2020 – 2024 (US$ Mn)
Figure 07: Global Chronic Kidney Disease Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 08: Global Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 09: Global ACE Inhibitors Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 10: Global Angiotensin-II Receptor Blockers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 11: Global Calcium Channel Blockers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 12: Global Beta Blockers Market Revenue (US$ Mn) and Y-o-Y Growth (%) 2014–2024
Figure 13: Global Erythropoiesis-stimulating agents (ESAs) Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 14: Global Diuretics Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 15: Global Other Drug Class Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 16: Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Drug Class
Figure 17: Global Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by End-user, 2016 and 2024
Figure 18: Global Hospitals Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 19: Global Specialty Clinics Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 20: Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by End-user
Figure 21: Global Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Region, 2016 and 2024
Figure 22: Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Region
Figure 23: North America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2024
Figure 24: North America Market Attractiveness Analysis, by Country
Figure 25: North America Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 26: North America Market Value Share Analysis, by End-user, 2016 and 2024
Figure 27: North America Market Value Share Analysis, by Country, 2016 and 2024
Figure 28: North America Market Attractiveness Analysis, by Drug Class 
Figure 29: North America Market Attractiveness Analysis, by End-user
Figure 30: Europe Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2024
Figure 31: Europe Market Attractiveness Analysis, by Country
Figure 32: Europe Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 33: Europe Market Value Share Analysis, by End-user, 2016 and 2024
Figure 34: Europe Market Value Share Analysis, by Country, 2016 and 2024
Figure 35: Europe Market Attractiveness Analysis, by Drug Class
Figure 36: Europe Market Attractiveness Analysis, by End-user
Figure 37: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2014–2024
Figure 38: Asia Pacific Market Attractiveness Analysis, by Country
Figure 39: Asia Pacific Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 40: Asia Pacific Market Value Share Analysis, by End-user, 2016 and 2024
Figure 41: Asia Pacific Market Value Share Analysis, by Country, 2016 and 2024
Figure 42: Asia Pacific Market Attractiveness Analysis, by Drug Class
Figure 43: Asia Pacific Market Attractiveness Analysis, by End-user
Figure 44: Latin America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2014–2024
Figure 45: Latin America Market Attractiveness Analysis, by Country
Figure 46: Latin America Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 47: Latin America Market Value Share Analysis, by End-user, 2016 and 2024
Figure 48: Latin America Market Value Share Analysis, by Country, 2016 and 2024
Figure 49: Latin America Market Attractiveness Analysis, by Drug Class
Figure 50: Latin America Market Attractiveness Analysis, by End-user
Figure 51: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2014–2024
Figure 52: Middle East & Africa Market Attractiveness Analysis, by Country
Figure 53: Middle East & Africa Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 54: Middle East & Africa Market Value Share Analysis, by End-user, 2016 and 2024
Figure 55: Middle East & Africa Market Value Share Analysis, by Country, 2016 and 2024
Figure 56: Middle East & Africa Market Attractiveness Analysis, by Drug Class
Figure 57: Middle East & Africa Market Attractiveness Analysis, by End-user
Figure 58: Global Chronic Kidney Disease (CKD) Drugs Market Share Analysis, by Company (2015)

List of Tables

Table 01: Global Chronic Kidney Disease (CKD) Pipeline Drugs Market Size (US$ Mn) Forecast, 2018–2024
Table 02: Global Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 03: Global Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2016–2024
Table 04: Global Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Region, 2016–2024
Table 05: North America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 06: North America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2016–2024
Table 07: North America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 08: Europe Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 09: Europe Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2016–2024
Table 10: Europe Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 11: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 12: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2016–2024
Table 13: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 14: Latin America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 15: Latin America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2014–2024
Table 16: Latin America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 17: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 18: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2014–2024
Table 19: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024

Global Chronic Kidney Disease (CKD) Drugs Market: Overview

This report on the global chronic kidney disease (CKD) drugs market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2014 to 2024, considering the macro and micro environmental factors. Growth rates for each segment within the global chronic kidney disease (CKD) drugs market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also provide insights into the key trends of the chronic kidney disease (CKD) drugs market such as novel treatment approaches such as monoclonal antibodies, RNA-based therapies and stem cell based therapies. The key market indicators influencing global Chronic Kidney Disease (CKD) Drugs market taken into consideration including cost constraints and regulatory landscape. The report also includes market attractiveness analysis of the major segments that provides a thorough analysis of the overall competitive scenario in the global Chronic Kidney Disease (CKD) Drugs market. The report also highlights key events of the global Chronic Kidney Disease (CKD) Drugs industry. A porter’s five force analysis highlighting competitive landscape is also included in the report.

Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all the segments, considering 2015 as the base year. The year on year growth of global Chronic Kidney Disease (CKD) Drugs market for each segment is also reflected. Additionally, market related factors such as increasing preference for product innovation, and cost reduction for hospitals and greater affordability for patients in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.

Global Chronic Kidney Disease (CKD) Drugs Market: Segmentation

Based on product type, the global Chronic Kidney Disease (CKD) Drugs market has been segmented into ACE Inhibitors, Angiotensin-II receptor blockers, Calcium channel blockers, Beta blockers, Erythropoiesis-stimulating agents (ESAs), Diuretics, and Others. Based on end-user, the market has been segmented into hospitals and specialty clinics. Hospitals segment is expected to remain dominant during the forecast period.

Geographically, the global Chronic Kidney Disease (CKD) Drugs market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented into major countries from each region. These include the U.S., Canada, the U.K., Germany, France, Italy, Spain, China, Australia, India, Japan, Brazil, and Mexico.

Global Chronic Kidney Disease (CKD) Drugs Market: Competitive Landscape

The report also profiles major players in the Chronic Kidney Disease (CKD) Drugs market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. A thorough market share analysis of major companies operating in the Chronic Kidney Disease (CKD) Drugs market is provided in the report. Key companies profiled in the report include Keryx Biopharmaceuticals, Inc., Kissei Pharmaceutical Co., Ltd, AbbVie, Inc., GlaxoSmithKline plc., Sanofi S.A. , F. Hoffmann-La Roche Ltd., Pfizer, Inc., AstraZeneca plc, Amgen Inc., and Teva Pharmaceutical Industries Ltd.

The global Chronic Kidney Disease (CKD) Drugs market has been segmented as follows:

By Drug class

  • ACE Inhibitors
  • Angiotensin-II receptor blockers
  • Calcium channel blockers
  • Beta blockers
  • Erythropoiesis-stimulating agents (ESAs)
  • Diuretics
  • Others

By End User

  • Hospitals
  • Specialty Clinics

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Australia
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of Middle East & Africa


 
 
Back To Top